Time for my occasional update on current and upcoming neuroprotection trials for PSP. The tables here are slides from a lecture I gave a few days ago on that topic at the University of Chicago.

This first table shows trials that have completed patient recruitment but for which there are no available results. This is usually because the analysis is incomplete or some of the patients are still having their study visits, but in a few cases it’s for the company’s own business reasons.

The second table shows PSP trials currently recruiting or likely to start doing so in the next year or two. Note that the trial of selenium supplementation, in the first row, is happening only in Australia. The only one recruiting anywhere else right now is FNP-223. If you’re interested in enrolling in that one, call the sponsor company in Spain at +34 609 850 565 or email them at medinfo@ferrer.com. They can tell you which of their study sites is closest to your home and then you’d contact that site’s coordinator directly.

Note that the GV1001 trial is presently only in South Korea, but the company says it will come to the US in late 2025.

Also note that the AZP-2006 and AADvac1 trials are the first two of what will soon be three drugs in the PSP Trial Platform. The third will be announced soon and the trial is scheduled to get under way in late 2025.

If you’re thinking of volunteering for a trial, do it sooner rather than later. Several reasons:
• The drug is more likely to work in earlier-stage PSP.
• The trials all require participants to have no more than a certain level of symptom severity and duration.
• If you insist on waiting for the perfect drug trial, you will be waiting a long time!